Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2026 | $210.00 | In-line → Outperform | Evercore ISI |
| 9/23/2025 | $185.00 | In-line | Evercore ISI |
| 8/20/2025 | $200.00 | Buy | BofA Securities |
| 5/2/2025 | $130.00 | Equal Weight → Overweight | Wells Fargo |
| 12/3/2024 | $86.00 | Equal Weight | Wells Fargo |
| 10/4/2024 | $78.00 | Neutral | Goldman |
| 6/20/2024 | $115.00 | Peer Perform → Outperform | Wolfe Research |
| 12/11/2023 | $110.00 | Neutral → Buy | Citigroup |
Evercore ISI upgraded iRhythm from In-line to Outperform and set a new price target of $210.00
Evercore ISI initiated coverage of iRhythm with a rating of In-line and set a new price target of $185.00
BofA Securities initiated coverage of iRhythm with a rating of Buy and set a new price target of $200.00
15-12G - iRhythm Holdings, Inc. (0001388658) (Filer)
S-8 POS - iRhythm Holdings, Inc. (0001388658) (Filer)
S-8 POS - iRhythm Holdings, Inc. (0001388658) (Filer)
SAN FRANCISCO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2025 after the close of trading on Thursday, February 19, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. iRhythm is
SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference. Recent Operational Highlights and Financial Outlook Anticipate full year 2025 revenue to exceed high end of previously stated guidance range of $740 million provided in October 2025, driven by record revenue unit volume during the fourth quarter 2025For full year 2026, expect revenue of approximately $870 million to $880 million, or approximat
SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming 44th Annual J.P. Morgan Healthcare Conference. iRhythm's management is scheduled to present on Monday, January 12, 2026, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Events and Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc.iRhythm is a leading digi
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)
SAN FRANCISCO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the fourth quarter and full year 2025 after the close of trading on Thursday, February 19, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Holdings, Inc. iRhythm is
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $192.9 million, a 30.7% increase compared to third quarter 2024Gross margin of 71.1%, a 230-basis point increase compared to third quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $565.2 million as of September 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights
SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, October 30, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leadin
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved
A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer
SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering